SGLT2 inhibitors, for instance, have demonstrated not only robust glycemic control but also substantial cardiovascular and renal benefits, making them particularly suitable for patients with comorbidities such as heart failure or chronic kidney disease. This evidence concerns the gene SLC5A2 and heart failure.